These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20805547)

  • 1. Was the FDA misled by JUPITER?
    MacDonald GP
    J Am Osteopath Assoc; 2010 Aug; 110(8):424-5. PubMed ID: 20805547
    [No Abstract]   [Full Text] [Related]  

  • 2. [JUPITER study (2). For now no reason to give statins to more people].
    Koopmans RP
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):218-9. PubMed ID: 19271439
    [No Abstract]   [Full Text] [Related]  

  • 3. [JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
    Håkansson J
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1460-1. PubMed ID: 19579433
    [No Abstract]   [Full Text] [Related]  

  • 4. [JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
    Lubsen J
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):216-7. PubMed ID: 19271438
    [No Abstract]   [Full Text] [Related]  

  • 5. Most would fail to benefit from JUPITER Intervention.
    Plonk WM
    J Am Coll Cardiol; 2009 Aug; 54(8):744; author reply 744-5. PubMed ID: 19679258
    [No Abstract]   [Full Text] [Related]  

  • 6. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
    MacDonald GP
    J Am Osteopath Assoc; 2010 Aug; 110(8):427-36. PubMed ID: 20805548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JUPITER Trial: responding to the critics.
    Ridker PM; Glynn RJ
    Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837
    [No Abstract]   [Full Text] [Related]  

  • 9. [The JUPITER study].
    Gaspardone A; Maseri A
    G Ital Cardiol (Rome); 2009 May; 10(5):267-70. PubMed ID: 19537439
    [No Abstract]   [Full Text] [Related]  

  • 10. [JUPITER study, more reason to give statins as preventive measure - commentary].
    Narkiewicz K
    Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067
    [No Abstract]   [Full Text] [Related]  

  • 11. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
    Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract]   [Full Text] [Related]  

  • 12. Public health. U.S. panel favors wider use of preventive drug treatment.
    Couzin-Frankel J
    Science; 2010 Jan; 327(5962):130-1. PubMed ID: 20056859
    [No Abstract]   [Full Text] [Related]  

  • 13. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 14. Rosuvastatin in patients with elevated C-reactive protein.
    Koller MT; Bucher HC; Steyerberg EW
    N Engl J Med; 2009 Mar; 360(10):1041; author reply 1041-2. PubMed ID: 19271276
    [No Abstract]   [Full Text] [Related]  

  • 15. Rosuvastatin in patients with elevated C-reactive protein.
    Pierard LA
    N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271277
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosuvastatin in patients with elevated C-reactive protein.
    Jenny-Avital ER
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275
    [No Abstract]   [Full Text] [Related]  

  • 17. Rosuvastatin in patients with elevated C-reactive protein.
    Chan PS; Nallamothu BK; Hayward RA
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271273
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
    Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
    Ridker PM;
    Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
    [No Abstract]   [Full Text] [Related]  

  • 20. Rosuvastatin in patients with elevated C-reactive protein.
    Gibbons RJ
    N Engl J Med; 2009 Mar; 360(10):1038; author reply 1041-2. PubMed ID: 19264695
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.